Andrew John Armstrong, MD

Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Grants

Publications

Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.

PMID
31705765
Full Text

Higano, Celestia S., Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher M. Pieczonka, et al. “Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.” Cancer, March 10, 2020. https://doi.org/10.1002/cncr.32785.

PMID
32154908
Full Text

Lu, Changxue, Landon C. Brown, Emmanuel S. Antonarakis, Andrew J. Armstrong, and Jun Luo. “Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.” Prostate Cancer Prostatic Dis, March 5, 2020. https://doi.org/10.1038/s41391-020-0217-3.

PMID
32139878
Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.

PMID
31522863
Full Text

Sartor, Oliver, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, et al. “Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.” Prostate Cancer Prostatic Dis, February 28, 2020. https://doi.org/10.1038/s41391-020-0213-7.

PMID
32111923
Full Text

Freedland, Stephen J., Jenifer Allen, Aubrey Jarman, Taofik Oyekunle, Andrew J. Armstrong, Judd W. Moul, Howard Sandler, et al. “A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2).” Clin Cancer Res, February 27, 2020. https://doi.org/10.1158/1078-0432.CCR-19-3873.

PMID
32108029
Full Text

Armstrong, Andrew J., Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg, Joyce Steinberg, Bertrand Tombal, et al. “Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.” Jama Oncol, December 12, 2019. https://doi.org/10.1001/jamaoncol.2019.4636.

PMID
31830211
Full Text

Li, Yanjing, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, et al. “Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.” Sci Transl Med 11, no. 521 (December 4, 2019). https://doi.org/10.1126/scitranslmed.aax0428.

PMID
31801883
Full Text

Higano, Celestia S., Andrew J. Armstrong, A Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher M. Pieczonka, et al. “Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.” Cancer 125, no. 23 (December 1, 2019): 4172–80. https://doi.org/10.1002/cncr.32445.

PMID
31483485
Full Text

Holl, Eda K., Megan A. McNamara, Patrick Healy, Monika Anand, Raoul S. Concepcion, Coleman D. Breland, Igor Dumbudze, et al. “Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.” Prostate Cancer Prostatic Dis 22, no. 4 (December 2019): 588–92. https://doi.org/10.1038/s41391-019-0144-3.

PMID
30980027
Full Text

Pages